Literature DB >> 25669106

[Effects of buspirone complex with glycyrrhizic acid on behavior of mice with anxious-depressive state].

M K Fomina, D F Avgustinovich, T G Tolstikova.   

Abstract

We report here studies of the effects of subchronic administration of 5-HT1A receptor agonist buspirone and its novel complex with glycyrrhizic acid (GA) to C57BL/6J mice at the different stages of the anxious-depressive state formation, induced by conditions of social stress. The experiment of agents' administration during the conditions of stress (beginning with initial stage) showed that only complex had a protective effect revealed in prevention of the anxiety with the high level of mice communicativeness maintenance. At the stage when the anxious-depressive state is completely formed, buspirone and its complex with GA decreased mice motor activity however complex--less significantly. Here we discuss a possible mechanism of action of investigated agents on the background of changes in the sensitivity of 5-HT1A receptors, induced by the formation of the anxious-depressive state of mice with experience of social stress. Despite of different effects of agents depending on the stage of the anxious-depressive state development, novel buspirone complex with GA has some advantage over buspirone.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25669106

Source DB:  PubMed          Journal:  Ross Fiziol Zh Im I M Sechenova        ISSN: 0869-8139


  2 in total

1.  Atorvastatin calcium inclusion complexation with polysaccharide arabinogalactan and saponin disodium glycyrrhizate for increasing of solubility and bioavailability.

Authors:  Ruiping Kong; Xingyi Zhu; Elizaveta S Meteleva; Nikolay E Polyakov; Mikhail V Khvostov; Dmitry S Baev; Tatjana G Tolstikova; Alexander V Dushkin; Weike Su
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

2.  Effects of Xiaoyaosan on Stress-Induced Anxiety-Like Behavior in Rats: Involvement of CRF1 Receptor.

Authors:  You-Ming Jiang; Xiao-Juan Li; Zhen-Zhi Meng; Yue-Yun Liu; Hong-Bo Zhao; Na Li; Zhi-Yi Yan; Qing-Yu Ma; Han-Ting Zhang; Jia-Xu Chen
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-02       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.